Three types of innovative medicines listed on the market have been evaluated through the consistency of generic drugs. 34 Yichang new drug research and development is in the forefront of the province

The Three Gorges Daily (Reporter He Guanying) On July 19, the reporter learned from the Municipal Market Supervision and Administration Bureau that since 2020, Yichang has been approved for listing, of which 3 innovative drugs and 1 improved new drug. A total of 34 varieties were evaluated through the quality and efficacy consistency of generic drugs, ranking first in the province.

The research and development of chemical 1 drugs is an important benchmark for measuring innovation capabilities and industry levels in a regional region. "At present, there are three types of chemistry 1 innovative medicine in the province, all in Yichang. The phosphate developed by Pharmaceuticals Emimweve Capsules. "Guo Hui, deputy director of the Municipal Market Supervision and Administration Bureau, introduced. Among them, Yichang Renfu Pharmaceutical Entry Pepsulfonzilon is the first new drug in the province, which broke the situation in the field of sedative drugs at home and abroad for nearly 30 years.

At present, Yichang Renfu is developing the research and development of more than 220 new products, including 11 new categories, 18 new categories and more than 50 new categories. There are more than 120 patents and 9 international patents. At the same time, the development of the city's medical device industry has also achieved good results. Seven third medical device products that have obtained registration and approval, 102 secondary medical device products, 140 first medical device products, and 249 registered numbers of product filing and registration. The ability of sanitary dressing, tracheal intubation, and customized denture supplies.

Behind the impressive results, the relevant departments are inseparable from the silent service. Our city has successively introduced the "Measures for the Evaluation of the Quality and Consistency Evaluation of Imitation Drugs" and "Several Policies and Measures on the Construction of the National Impropon Pharmaceutical Production Base" to fully support the development of biomedical enterprises. Up to now, a total of 77.5 million yuan has been distributed to the quality and efficacy of the quality and efficacy of generic drugs to various pharmaceutical manufacturers.

In order to further optimize the business environment and serve the development of biomedical enterprises, the Market Supervision and Administration Bureau gathers the functions of cosmetics permits, supervision, standards, measurement, patents, intellectual property rights such as cosmetics and medical equipment in the department, and provides policies for intensive development of biomedical enterprises. Technical consulting and guidance; lead the city's direct departments to serve the development, production permits, product registration verification of product development, production permits, and product registration of biomedical enterprises; actively assign drugs and medical equipment inspectors to support related projects as soon as possible.

A series of powerful measures stimulate the innovative vitality and research and development momentum of biomedical enterprises, and also press the "acceleration key" for the investment in the biomedical industry. In 2021, the city completed 31 contract projects, with an agreement investment of 12.051 billion yuan, of which 8 were started and 1 were put into production projects.

- END -